Erratum to: Clinical efficacy of arbekacin for Gram-negative bacteria (Journal of Infection and Chemotherapy (2011) 17(6) (876–879) (S1341321X11704299) (10.1007/s10156-011-0262-x));Clinical efficacy of arbekacin for Gram-negative bacteria

Journal of Infection and Chemotherapy

Volumn 17, Issue 6, 2011, Pages 876-879

  Hamada, Yukihiro ^a   Tamura, Kazuyoshi ^a   Koyama, Ikumi ^b   Kuroyama, Masakazu ^a,b   Yago, Kazuo ^a,b   Sunakawa, Keisuke ^b  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Arbekacin; Blood concentration level; Gram negative bacteria (GNB); Minimal inhibitory concentration (MIC)

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; GENTAMICIN; HABEKACIN; MACROLIDE; PENICILLIN G; QUINOLONE DERIVATIVE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG EFFICACY; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; TREATMENT OUTCOME;

EID: 84855278408     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0279-1     Document Type: Erratum

References (22)

1. Inouye S, Tamura A, Niizato T, Takeuchi T, Hamada M, Kondo S. Antibacterial activity and nephrotoxicity of two novel 2″-amino derivatives of arbekacin. J Infect Chemother. 1996;2:84-9. (Pubitemid 126721869)
2. K Yokoyama Y Doi K Yamane H Kurokawa N Shibata K Shibayama, et al. 2003 Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa Lancet 362 1888 1893 14667745 10.1016/S0140-6736(03)14959-8 1:CAS:528:DC%2BD3sXps1Cjtrw%3D (Pubitemid 37518504)
3. N Tanaka K Matsunaga A Hirata Y Matsuhisa T Nishimura 1983 Mechanism of action of habekacin, a novel amino acid-containing aminoglycoside antibiotic Antimicrob Agents Chemother 24 797 802 6362557 1:CAS:528:DyaL2cXjt1SqsQ%3D%3D (Pubitemid 14203885)
4. T Watanabe K Ohashi K Matsui T Kubota 1997 Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus J Antimicrob Chemother 39 471 476 9145819 10.1093/jac/39.4.471 1:CAS:528:DyaK2sXjtlygsrw%3D (Pubitemid 27196944)
5. S Fujimura K Gomi H Takane Y Nakano K Fuse T Kikuchi, et al. 2009 Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007 Jpn J Chemother 57 91 96 1:CAS:528:DC%2BD1MXjtlalurk%3D
6. N Tsuchimochi T Takuma N Shimono Y Nagasaki Y Uchida M Harada 2008 Antimicrobial susceptibility and epidemiological analysis of clinical strains of Pseudomonas aeruginosa J Infect Chemother 14 99 104 18622671 10.1007/s10156-007-0578-8 1:CAS:528:DC%2BD1cXlt1antr0%3D (Pubitemid 351624456)
7. Araoka H, Baba M, Takagi S, Matsuno N, Ishiwata K, Nakano N, et al. Monobactam and aminoglycoside combination therapy against metallo-β- lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a "break-point checkerboard plate." Scand J Infect Dis. 2020;42:231-3.
8. K Shimizu N Aikawa Y Tanigawara M Kaku M Imae N Nishizawa, et al. 2003 Actual use of anti-MRSA drugs in Japan with the focus on arbekacin Jpn J Chemother 51 717 730 (Pubitemid 38016360)
9. K Ohno T Nakamura T Azuma T Yoshida H Yamada H Hayashi, et al. 2008 Surveillance of bacteriological examinations at hospitalization in a pediatric surgical ward J Pediatr Surg 43 1507 1510 18675643 10.1016/j.jpedsurg.2007.11. 018
10. Y Hamada K Tamura K Otori H Matsubara K Sunakawa K Yago 2008 In improving inflammatory response early after the start of treatment that relative rate changes in CRP levels in anti-MRSA agents Antibiot Chemother 24 102 108
11. AW Bauer WM Kirby JC Sherris M Turck 1966 Antibiotic susceptibility testing by a standardized single disk method Am J Clin Pathol 45 493 496 5325707 1:STN:280:DyaF287htV2isA%3D%3D
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement (M100-S20). Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
13. DM Richard SL Paul RS Craig 1987 Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration CID 155 93 99
14. H Kawano Y Tanigawara 2010 Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring Jpn Soc TDM 27 55 71
15. T Matsuno N Suzuki S Kawai S Han Y Mizutani H Fujii, et al. 2008 A method of effective administration for arbekacin (ABK)-2 Jpn J TDM 43 1507 1510
16. N Aikawa S Kohno M Kaku A Watanabe K Yamaguchi Y Tanigawara 2008 An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA): a clinical pharmacology study Jpn J Chemother 56 299 312 (Pubitemid 351795980)
17. Y Aoki 1994 Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus. Comparison with that of vancomycin Jpn J Antibiot 47 640 646 8072172 1:CAS:528:DyaK2cXltVeqsLg%3D (Pubitemid 24240153)
18. Kondo S, Iinuma K, Yamamoto H, Maeda K, Umezawa H. Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3′,4′- dideoxykanamycin B active against kanamycin-resistant bacteria (Letter). J Antibiot (Tokyo). 1973;26:412-5.
19. R Okamoto S Iyobe S Mihashi 1986 Antibacterial activity of HBK Chemotherapy 34 Suppl 1 1 10 (Pubitemid 16145285)
20. T Kimura K Sunakawa N Matsuura H Kubo S Shimada K Yago 2004 Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates Antimicrob Agents Chemother 48 1159 1167 15047516 10.1128/AAC.48.4.1159-1167.2004 1:CAS:528:DC%2BD2cXjtVKru70%3D (Pubitemid 38405469)
21. M Barza RB Brown D Shen M Gibaldi L Weinstein 1975 Predictability of blood levels of gentamicin in man J Infect Dis 132 165 174 808583 10.1093/infdis/132.2.165 1:STN:280:DyaE28%2Fgs1GgsQ%3D%3D
22. T Kimura M Sato M Nonoyama K Yago M Ishii K Sunakawa 2006 Evaluation of initial dosage in neonates based on population pharmacokinetics of arbekacin Jpn J Chemother 54 520 525 (Pubitemid 44842822)